Theprubicin
Enteropathy-Associated T-Cell Lymphoma
Explore 20 assets in Enteropathy-Associated T-Cell Lymphoma →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Ruijin Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Enteropathy-Associated T-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Theprubicin (this asset) | Ruijin Hospital | Approved | BB · 65 |
| Adriamycin | Eric Jacobsen, MD | P4 | BBB |
| Etoposide | Eric Jacobsen, MD | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | Eric Jacobsen, MD | P4 | BB |
| Isocyclophosphamide | Shandong Provincial Hospital | P4 | BB |
| (+)-Vincristine | Eric Jacobsen, MD | P4 | BB |
| Brentuximab Vedotin | Northwestern University | P2 | B |
| Azacitidine | National Cancer Institute (NCI) | P2 | B |
+27 more in the Enteropathy-Associated T-Cell Lymphoma cohort
Other indications for Theprubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P4 | BB · 71 |
| ALK-Negative Anaplastic Large Cell Lymphoma | — | P4 | BB · 65 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Theprubicin in Enteropathy-Associated T-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/theprubicin-enteropathy-associated-t-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →